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Objectives. To examine whether age of First diagnosis, gender, psychiatric comorbidity, and treatment modalities (pharmacother-
apy or psychotherapy) at Child and Adolescent Mental Health Services (CAMHS) moderate the risk of Adult Mental Health
Services (AMHS) utilization in patients diagnosed with hyperkinetic disorder at CAMHS. Methods. Data were derived from the
Madrid Psychiatric Cumulative Register Study. The target population comprised 32,183 patients who had 3 or more visits at
CAMHS. Kaplan-Meier curves were used to assess survival data. A series of logistic regression analyses were performed to study
the role of age of diagnosis, gender, psychiatric comorbidity, and treatment modalities. Results. 7.1% of patients presented with
hyperkinetic disorder at CAMHS. Compared to preschool children, children and adolescents first diagnosed with hyperkinetic
disorder at CAMHS were more likely to use AMHS. Female gender and comorbidity with aﬀective disorders, schizophrenia,
schizotypal and delusional disorders increased the risk of use of AMHS. Pharmacological or combined treatment of hyperkinetic
disorder diagnosed at CAMHS was associated with increased risk of use at AMHS. Conclusions. Older age of first diagnosis, female
gender, psychiatric comorbidity, and pharmacological treatment at CAMHS are markers of risk for the transition from CAMHS
to AMHS in patients with hyperkinetic disorder diagnosed at CAMHS.
1. Introduction
Research regardingmental health services use is of significant
interest given the ongoing eﬀorts to control rising costs
of mental health care. Thus, factors related to the trans-
ition from Child and Adolescent Mental Health Services
(CAMHSs) to Adult Mental Health Services (AMHSs) are a
major concern [1]. Longitudinal data assessing continuities
of childhood disorders into adulthood [2] may allow to
implement early intervention and preventive programmes
[3], thus reducing the economic burden of childhood mental
disorders progressing into adulthood.
In this context, the study of the continuities of either
attention-deficit/hyperactivity disorder (ADHD, DSM-IV), a
condition aﬀecting between 4% and 8% of children world-
wide [4–6], or hyperkinetic disorder (HD) (ICD-10), with
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a 1% worldwide prevalence rate, appears to be relevant
[7]. Longitudinal studies followingup children with ADHD
have consistently reported high rates of ADHD at follow up
[7, 8]. The rate of syndromatic remission of ADHD is around
60% [9, 10]. The majority of subjects, however, continue
to struggle with a large number of ADHD symptoms in
adulthood [9]. Unfortunately, there is little information
about which factors could be associated with an increased
risk of utilization of AMHS in patients diagnosed with
HD at CAMHS. For instance, it is diﬃcult to determine
if age and gender are factors that may increase the risk of
utilization of AMHS. Although HD is less frequent in ado-
lescents compared with children [11], continuities of mental
disorders are stronger for juvenile diagnosis than for diag-
nosis made prior to adolescence [12]. Regarding gender,
although the clinical profile is similar in boys and girls
[13], HD is less prevalent among girls [11, 14, 15]. A
priori, severity of symptoms and psychiatric comorbidity
are predictors of ADHD persistence [16] and, therefore,
should intuitively be associated with an increased use of
AMHS. Unfortunately, the bulk of studies have not addressed
whether comorbidity moderates treatment outcomes in chil-
dren with hyperactivity [17]. Finally, pharmacological treat-
ment of HD could intuitively be considered a marker of poor
prognosis, as children with HD under pharmacological treat-
ment usually display a more severe clinical profile than chil-
dren with HD treated with psychotherapy. However, pharm-
acological treatment could also improve HD, thus preventing
the transition from CAMHS to AMHS.
The main purpose of this epidemiological study was to
examine whether age of first diagnosis at CAMHS, gender,
psychiatric comorbidity diagnosed at CAMHS, and treat-
ment modalities (pharmacotherapy or psychotherapy) at
CAMHS moderate the risk of AMHS utilization in patients
diagnosed with HD at CAMHS.
2. Methods
Data were derived from the Madrid Psychiatric Cumulative
Register (MCR) Study. The MCR study has been described
in detail elsewhere [18–20]. Briefly, the MCR study is a
naturalistic study of diagnostic stability over time. Between
January 1986 and December 2007, public mental health
centers in the province of Madrid, Spain, recorded all
psychiatric visits in a registry. Nonstandardized clinical di-
agnoses and type of care provided were registered in every
follow-up visit by experienced psychiatrists and clinical
psychologists. All subjects can be traced because each patient
is given a unique, anonymous identifying number, which is
the same throughout all contacts with mental health services
within the study area.
2.1. Diagnostic Procedure. Lifetime psychiatric diagnoses
were made according to the International Classification of
Diseases, Tenth Revision (ICD-10, World Health Organiza-
tion, 1992). The diagnosis of either HD or any other mental
health disorder was established after three consecutive visits
within the same episode at CAMHS.
2.2. Participants. The target population comprised 32,183
children and adolescents (50.3% females and 49.7% males)
who had 3 or more consecutive visits at CAMHS and were
18 years old or older at the time of the present study. We
classified patients into four groups according to their first
contact with CAMHS and using the US National Library of
Medicine and the National Institutes of Health Classification:
from birth to 23 months (HD infant group), from 2 to 5
years old (HD preschool children group), from 6 to 12 years
old (HD children group), and from 13 to 17 years old (HD
adolescent group).
2.3. Predictors of Treatment Use at AMHS. We examined
three types of predictors of treatment use at AMHS among
individuals diagnosed with HD during childhood and ad-
olescence: sociodemographic characteristics (age of first
diagnosis, gender), psychiatric comorbidity, and treatment
modalities during followup at CAMHS.
2.4. Data Analyses. First, we used Kaplan-Meier survival
curves to compare the likelihood of AMHS use among
subjects diagnosed with and without HD at CAMHS. Among
individuals with a diagnosis of HD during childhood or
adolescence, a series of logistic regression analyses were sub-
sequently performed to examine whether age of first psy-
chiatric diagnosis, gender, and the presence of comorbid
psychiatric disorders during followup at CAMHS increased
the risk of AMHS use. We calculated odds ratios (ORs) and
95% confidence intervals (CIs) for ease of interpretation.
Statistical significance was evaluated at the .05 level using
two-tailed tests. Finally, we used Fisher’s Exact Test (FET)
to evaluate the role of treatment (pharmacotherapy, psy-
chotherapy, or both) regarding the transition from CAMHS
to AMHS. We used SPSS statistical software, edition 17.0 for
Mac (2008) for all statistical analyses.
3. Results
3.1. Sample Characteristics. Patients averaged 20 lifetime vis-
its (SD±28, range: 4–1036). At the time of first evaluation at
CAMHS, 0.1% were infants, 4.4% preschool children, 33.9%
children, and 61.7% adolescents. 7.1% of the 32,183 pa-
tients were diagnosed with HD before adulthood (0.2% di-
agnosed as infants, 11.5% as preschool children, 60.0% as
children, and 28.2% as adolescents).
3.2. Utilization of AMHS. Subjects diagnosed with HD at
CAMHS (n = 2, 274) were less likely to be followedup at
AMHS (n = 425, 18.7%) than subjects without a diagnosis
of HD at CAMHS (n = 10796, 36.1%) (OR (CI 95%) = 0.43
(0.38–0.48); FET P < 0.001). (see Figure 1).
Children and particularly adolescents first diagnosed
with HD at CAMHS were more likely to seek mental
health treatment at AMHS than the HD preschool children
group (see Table 1). In addition, girls diagnosed with HD at
CAMHS used AMHS more frequently than boys diagnosed
with HD at CAMHS. Interestingly, subjects diagnosed with
HD at CAMHS were less likely to present a comorbid diag-
nosis of schizophrenia, schizotypal and delusional disorders
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Figure 1: Kaplan-Meier curve of adolescents (13–18 years old)
diagnosed with and without Hyperkinetic disorder. Cumulative
survival decreased steadily during the followup in both subjects
diagnosed with and without HD at CAMHS, but the decrease
was more evident in those subjects with HD. The transition from
CAMHS to AMHS takes place within a 1,830 day (5 years) period.
(F20–29) (OR = 0.585, 95% CI = 0.458–0.747), or aﬀective
disorders (F30–39) (OR = 0.449, 95% CI = 0.376–0.536)
during followup at CAMHS. However, comorbidity of HD
with any of the above-mentioned disorders (either F20–29
or F30–39 diagnoses) at CAMHS increased the risk of AMHS
utilization (see Table 1).
Finally, children and adolescents diagnosed with HD
at CAMHS and treated with pharmacological or combined
treatment were significantly more likely to seekmental health
treatment at AMHS than children and adolescents with HD
diagnosed at CAMHS who were not on pharmacological or
combined treatment (OR (95% CI) = 1,75 (1,59–1,92); FET
P < 0.001, and OR (95% CI) = 1,27 (1,16–1,39); FET P <
0.001, resp.). Conversely, psychotherapy was associated with
decreased risk of use at AMHS of those children diagnosed
with HD at CAMHS (OR (95% CI) = 0,67 (0,61–0,74), FET
P < 0.001).
4. Discussion
Our results show that older age of first diagnosis at CAMHS,
female gender, comorbidity between HD and other psychi-
atric diagnoses at CAMHS, and either pharmacological or
combined treatment of HD at CAMHS are factors associated
with an increased likelihood of followup at AMHS. These
results suggest that the previously mentioned factors could
be markers of a worse prognosis in subjects diagnosed with
HD at CAMHS.
The prevalence of HD in our sample (7.1%) was higher
than the prevalence of HD reported in some community
samples [21], but similar to the 6.5% lifetime administrative
prevalence rate reported by Do¨pfner et al. [7]. Other authors
have also reported similar figures to those reported here.
In an epidemiological study carried out in Rochester, the
authors found a cumulative incidence of ADHD in the ele-
mentary and secondary school children of 7.5% [22]. In the
US National Health Interview Survey, the authors reported a
prevalence of 6.7% [12]. In addition, few preschool children
were diagnosed with HD in the present study. This is not
surprising because pre-school children are not usually refer-
red for treatment [11], and this is also in accordance with the
literature [9]. In this study, the authors reported a median
age for diagnosis of ADHD of 12 years.
Consistent with the available literature, patients diag-
nosed with HD at CAMHS were less likely to use AMHS
than patients without HD at CAMHS. Although it is widely
recognized that ADHD and HD persist into adulthood, less
than 20% of adults with hyperactivity are diagnosed or
treated [23]. This figure is pretty similar to the 18.7% of
patients with HD who were followedup in AMHS reported
here. Several reasons may explain why subjects diagnosed
with HD at CAMHS are less likely to be followedup in
AMHS than subjects without HD at CAMHS. First, although
symptoms of inattention, impulsivity, and hyperactivity pre-
sent diﬀerently in adulthood, current diagnostic criteria are
geared toward symptom identification during childhood [6,
24, 25]. Second, many adults with hyperactivity are seen by
mental health practitioners who are not familiar with the
adult presentation of the disorder or are reluctant to diagnose
ADHD/HD in adults [1]. Third, symptoms of inattention
decline at a modest rate while those of hyperactivity and
impulsivity remit much more abruptly [6, 26, 27]. Fourth,
children with HD may receive diﬀerent diagnoses (het-
erotypic continuities) in adulthood. For instance, some cases
of adult ADHD are unrecognized and misdiagnosed with
conditions such as borderline personality disorder, atypical
depression, or cyclothymia [18]. Fifth, some children with
HD may have a better outcome than others, being therefore
less likely to use AMHS [6]. Sixth, children with ADHD are
more likely to have at least one parent exhibiting noteworthy
features of ADHD, if not the full diagnosis, than would
be expected by chance [28]. Thus, these families might
have greater diﬃculties following through on treatment and
hyperactive childrenmight be less likely to seek services upon
reaching adulthood. Finally, theremight be inconsistencies in
the referral process.
Children diagnosed with HD in CAMHS were more like-
ly followedup at AMHS if first diagnosed at an older age and
being of female gender. Kim-Cohen et al. [2] reported that
continuities between juvenile mental disorders and mental
disorders in adulthood are stronger when diagnoses aremade
after the age of 15. However, other authors have reported
that age is not a critical factor for prediction of persistence of
HD [16]. The importance of gender is particularly interesting
and might point to diﬀerential sex-related etiology in this
neurodevelopmental disorder. Furthermore, hyperactivity
is frequently a “hidden disorder” in girls [29]. It is well
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Table 1: Factors predicting followup at AMHS of adults diagnosed with hyperkinetic disorder at CAMHS.
Wald df OR (95% CI) P values
Children∗ (6–12 years old) 4.150 1 1.643 (1.019–2.648) 0.042
Adolescents∗ (13–17 years
old)
29.725 1 3.888 (2.386–6.335) 0.001
Gender (female) 5.455 1 1.414 (1.057–1.893) 0.020
F10–F19 (mental and
behavioural disorders due
to psychoactive drugs)
8.879 1 2.479 (1.364–4.504) 0.003
F20–F29 (schizophrenia,
schizotypal and delusional
disorders)
21.325 1 4.351 (2.331–8.123) <0.001
F30–F39 (mood (aﬀective)
disorders)
53.835 1 5.180 (3.338–8.038) <0.001
F40–F48 (neurotic,
stress-related and
somatoform disorders)
61.856 1 2.688 (2.101–3.439) <0.001
F70–F79 (mental
retardation)
35.956 1 3.075 (2.130–4.438) <0.001
∗Compared to preschool children. OR: odds ratio; 95% CI: 95% confidence interval.
established that the prevalence of ADHD and HD is higher
in boys [11, 14]. In addition, more boys than girls with
hyperactivity receive treatment [30], which may worsen the
prognosis of HD in women. This is unfortunate because
hyperactive girls do not diﬀer from boys in terms of response
to stimulants [31]. Furthermore, concurrent comorbidity
and continuity of mental disorders, including ADHD/HD,
are more apparent in girls than in boys at least in the
transition from childhood to adolescence [32]. In addition,
women are overrepresented in adult samples of hyperactive
disorders [16] and seek treatment for hyperactivity more
frequently than men [9]. Another explanation is that women
diagnosed with childhood HD might suﬀer from a more
severe subtype thanmen in our study. Finally, as suggested by
Kessler et al. [16], it is also possible that, as antisocial behav-
ior is more frequent in hyperactive men, more men than wo-
men enter jail and are no longer ascertainable in either epi-
demiologic or clinical studies. Finally, cultural factors might
also contribute to gender diﬀerences in service seeking.
Patients diagnosed with HD and concurrent comorbidity
were also more likely followed up at AMHS. Comorbidity is
a distinct feature of ADHD and HD [6]. Subjects diagnosed
with ADHD and comorbid conditions during childhood are
more likely diagnosed with ADHD (homotypic continuities)
and other psychiatric disorders (heterotypic continuities) in
the adulthood [33]. Here, it is important to quote that the
ICD-10 exclude the diagnosis of HD in the presence of some
comorbid diagnoses such as mood or psychotic disorders.
This exclusion criterion might explain why we found a
low comorbidity rate of aﬀective and psychotic disorders in
patients diagnosed with HD at CAMHS. However, the risk of
utilization of AMHS was particularly high for those children
and adolescents presenting with HD and comorbid aﬀective
disorders (F30–39; ICD-10) and schizophrenia, schizotypal
and delusional disorders (F20–29; ICD-10) at CAMHS, thus
suggesting that children with HD and comorbid mood and
psychotic disorders have a poorer outcome than hyperactive
children without such a comorbidity, and underscores the
need for treatment guidelines to address this issue. Our
findings are in accordance with the literature [6]. For
instance, children diagnosed with both schizophrenia and
hyperactivity have a poorer response to medication and
poorer outcome than those diagnosed with schizophrenia
alone [10].
Finally, subjects with HD who received pharmacological
treatment at CAMHS were more likely to seek treatment
at AMHS than those not receiving medication for the HD
at CAMHS. Kessler et al. [16] reported that treatment was
associated with persistence in the adulthood. These authors
suggested that treatment might be interpreted as a “proxy
of severity,” and we concur. Children diagnosed with milder
forms of HD at CAMHS might be more likely to receive
psychological treatment, thus being less likely to seek treat-
ment at AMHS. This might be interpreted either as an ex-
ample of the eﬀectiveness of psychological treatment in HD,
or as a confirmation that psychological treatment is used in
less severe HD cases with a better prognosis.
4.1. Strengths and Limitations. The major strength of the
present study is that, to our knowledge, this is the largest
naturalistic study of transition from CAMHS to AMHS in
children and adolescents with HD. Nevertheless, our results
should be interpreted in the context of some limitations.
First, ICD-10 diagnoses were clinical, nonstandardized diag-
noses. However, research and clinical definitions of ADHD
and HD rely on reported symptoms and diagnosis is usually
made on the basis of clinical impressions [34]. Indeed,
rating scales, although useful in documenting hyperactive
symptoms as well as the response to treatments, should
never be used for diagnosis without careful clinical confirma-
tion [6, 35]. Second, we cannot reject the possibility that
our treatment sample was biased due to selection eﬀects
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(Berkson’s bias) [11]. However, our sample size, and the fact
that diagnoses were made by several professionals through-
out a long period of time, makes this possibility unlikely.
Furthermore, it is possible that some patients followed
alternative pathways of treatment. Because most Spaniards
receive mental health care in public services, this possibility
is, however, unlikely [20]. Finally, we used some literature on
ADHD to back some of our comments on HD. This was due
to the comparatively larger literature on ADHD than on HD.
Otherwise, it could have been diﬃcult to put into context
some of our findings. Nevertheless, even if DSM-IV ADHDs
identify a broader group of hyperactive children than those
identified by the ICD-10 HD, there is substantial overlap
between both diagnoses [36].
5. Conclusions
An older age of first diagnosis, female gender, comorbidity,
and pharmacological treatment at CAMHSmight bemarkers
of a worse prognosis in subjects diagnosed with HD at
CAMHS. Results from the present study might contribute to
a reduction in the economic burden of HD by targeting those
children with an increased risk of AMHS utilization.
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